Precise patient selection based on simple, clinically available indicators (e.g., IFN-I/IL-6 signatures or markers of mitochondrial damage) and methodological caution will be crucial, as non-selective TLR blockade may carry a risk of infection. This evidence concerns the gene IL6 and infection.